Clarification on the definition of complete response in multiple Myeloma.
Durie BG et al. Leukemia. 2015 Oct 21. doi: 10.1038/leu.2015.290. [Epub ahead of print].

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Giralt S et al. Biol Blood Marrow Transplant. 2015 Sep 30. pii: S1083-8791(15)00641-2. doi: 10.1016/j.bbmt.2015.09.016. [Epub ahead of print

Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years.
Fujisawa M et al. Ann Hematol. 2015 Oct 24. [Epub ahead of print].

Extramedullary plasmacytoma mimicking colon carcinoma: an unusual presentation and review of the literature.
Parnell K et al. BMJ Case Rep. 2015 Oct 23;2015. pii: bcr2015210973. doi: 10.1136/bcr-2015-210973.

Real World Treatment Patterns and Comorbidities and Disease-Related Complications in Patients with Multiple Myeloma in the United States.
Song X et al. Curr Med Res Opin. 2015 Oct 21:1-31. [Epub ahead of print].

Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.
Perales MA et al. Biol Blood Marrow Transplant. 2015 Oct 17. pii: S1083-8791(15)00684-9. doi: 10.1016/j.bbmt.2015.10.014. [Epub ahead of print].

Laboratory guidelines for the diagnosis and follow-up of patients with monoclonal gammopathies.
Bravo García-Morato M et al. Rev Clin Esp. 2015 Oct 16. pii: S0014-2565(15)00227-1. doi: 10.1016/j.rce.2015.09.002. [Epub ahead of print].

A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma.
Lu-Qun W et al. BMC Cancer. 2015 Oct 16;15(1):724. doi: 10.1186/s12885-015-1743-6.

Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy.
Stella F et al. Cancer Invest. 2015 Oct 27:1-9. [Epub ahead of print].

Prevalence, Supplementation, and Impact of Vitamin D Deficiency in Multiple Myeloma Patients.
Lauter B et al. Cancer Invest. 2015 Oct 27:1-5. [Epub ahead of print].

A pooled analysis of reproductive factors, exogenous hormone use and risk of multiple myeloma among women in the International Multiple Myeloma Consortium.
Costas L et al. Cancer Epidemiol Biomarkers Prev. 2015 Oct 13. pii: cebp.0953.2015. [Epub ahead of print].

Not all ST-segment changes are myocardial injury: hypercalcaemia-induced ST-segment elevation.
Strand AO et al. BMJ Case Rep. 2015 Oct 13;2015. pii: bcr2015211214. doi: 10.1136/bcr-2015-211214.

Novel agents in multiple myeloma treatment.
Ito S. Rinsho Ketsueki. 2015 Oct;56(10):2066-73. doi: 10.11406/rinketsu.56.2066.

Epigenetic therapy for hematologic malignancies.
Kobayashi Y et al. Rinsho Ketsueki. 2015 Oct;56(10):2015-23. doi: 10.11406/rinketsu.56.2015.

Clonal heterogeneity in plasma cell myeloma.
Quinn JG et al. Lancet. 2015 Oct 8. pii: S0140-6736(15)00384-0. doi: 10.1016/S0140-6736(15)00384-0. [Epub ahead of print].

Coexistent osteoporosis and multiple myeloma: when to investigate further in osteoporosis.
Mumford ER et al. BMJ Case Rep. 2015 Oct 8;2015. pii: bcr2015210896. doi: 10.1136/bcr-2015-210896.

Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT).
Aljurf M et al. Hematol Oncol Stem Cell Ther. 2015 Oct 1. pii: S1658-3876(15)00083-7. doi: 10.1016/j.hemonc.2015.09.002. [Epub ahead of print].

Targeting the tumor niche to treat cancer.
Neelapu SS et al. Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):12907-8. doi: 10.1073/pnas.1517389112. Epub 2015 Oct 8.

Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider.
Thompson MA et al. Curr Hematol Malig Rep. 2015 Oct 9. [Epub ahead of print].

Psychological screening of onco-hematologic inpatients: Distress Thermometer administration.
Bellè M et al. Tumori. 2015 Oct 5;0(0):0. doi: 10.5301/tj.5000440. [Epub ahead of print].

Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study.
Saccilotto IC et al. BMC Health Serv Res. 2015 Oct 5;15(1):455. doi: 10.1186/s12913-015-1123-6.

Inheritance in MGUS and MM.
Pfreundschuh M. Oncotarget. 2015 Oct 4. [Epub ahead of print].

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications.
Terpos E et al. Haematologica. 2015 Oct;100(10):1254-66. doi: 10.3324/haematol.2014.117176.

RAS mutations – for better or for worse in multiple myeloma?
Leich E et al. Leuk Lymphoma. 2015 Oct 2:1-2. [Epub ahead of print].

Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G et al. J Mol Med (Berl). 2015 Oct 1. [Epub ahead of print].

Risk of multiple myeloma in a case-spouse study.
Andreotti G et al. Leuk Lymphoma. 2015 Sep 30:1-27. [Epub ahead of print].

Evaluating the use of Plerixafor in stem cell mobilisation – an economic analysis of the PHANTASTIC trial.
Martin AP et al. J Clin Apher. 2015 Sep 29. doi: 10.1002/jca.21433. [Epub ahead of print].